Josiah E. Radder
University of Pittsburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Josiah E. Radder.
PLOS ONE | 2014
Callie A. Norris; Mu He; Liang-I Kang; Michael Qi Ding; Josiah E. Radder; Meagan Haynes; Yu Yang; Shirish Paranjpe; William C. Bowen; Anne Orr; George K. Michalopoulos; Donna B. Stolz; Wendy M. Mars
Exogenous interleukin 6 (IL-6), synthesized at the initiation of the acute phase response, is considered responsible for signaling hepatocytes to produce acute phase proteins. It is widely posited that IL-6 is either delivered to the liver in an endocrine fashion from immune cells at the site of injury, or alternatively, in a paracrine manner by hepatic immune cells within the liver. A recent publication showed there was a muted IL-6 response in lipopolysaccharide (LPS)-injured mice when nuclear NFκB was specifically inactivated in the hepatocytes. This indicates hepatocellular signaling is also involved in regulating the acute phase production of IL-6. Herein, we present extensive in vitro and in vivo evidence that normal hepatocytes are directly induced to synthesize IL-6 mRNAs and protein by challenge with LPS, a bacterial hepatotoxin, and by HGF, an important regulator of hepatic homeostasis. As the IL-6 receptor is found on the hepatocyte, these results reveal that induction of the acute phase response can be regulated in an autocrine as well as endocrine/paracrine fashion. Further, herein we provide data indicating that following partial hepatectomy (PHx), HGF differentially regulates IL-6 production in hepatocytes (induces) versus immune cells (suppresses), signifying disparate regulation of the cell sources involved in IL-6 production is a biologically relevant mechanism that has previously been overlooked. These findings have wide ranging ramifications regarding how we currently interpret a variety of in vivo and in vitro biological models involving elements of IL-6 signaling and the hepatic acute phase response.
American Journal of Respiratory Cell and Molecular Biology | 2017
Qingqing Meng; Yen-Chun Lai; Neil J. Kelly; Marta Bueno; Jeffrey Baust; Timothy N. Bachman; Dmitry A. Goncharov; Rebecca R. Vanderpool; Josiah E. Radder; Jian Hu; Elena A. Goncharova; Alison Morris; Ana L. Mora; Steven D. Shapiro; Mark T. Gladwin
&NA; Pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH‐HFpEF; World Health Organization Group II) secondary to left ventricular (LV) diastolic dysfunction is the most frequent cause of PH. It is an increasingly recognized clinical complication of the metabolic syndrome. To date, no effective treatment has been identified, and no genetically modifiable mouse model is available for advancing our understanding for PH‐HFpEF. To develop a mouse model of PH‐HFpEF, we exposed 36 mouse strains to 20 weeks of high‐fat diet (HFD), followed by systematic evaluation of right ventricular (RV) and LV pressure‐volume analysis. The HFD induces obesity, glucose intolerance, insulin resistance, hyperlipidemia, as well as PH, in susceptible strains. We observed that certain mouse strains, such as AKR/J, NON/shiLtJ, and WSB/EiJ, developed hemodynamic signs of PH‐HFpEF. Of the strains that develop PH‐HFpEF, we selected AKR/J for further model validation, as it is known to be prone to HFD‐induced metabolic syndrome and had low variability in hemodynamics. HFD‐treated AKR/J mice demonstrate reproducibly higher RV systolic pressure compared with mice fed with regular diet, along with increased LV end‐diastolic pressure, both RV and LV hypertrophy, glucose intolerance, and elevated HbA1c levels. Time course assessments showed that HFD significantly increased body weight, RV systolic pressure, LV end‐diastolic pressure, biventricular hypertrophy, and HbA1c throughout the treatment period. Moreover, we also identified and validated 129S1/SvlmJ as a resistant mouse strain to HFD‐induced PH‐HFpEF. These studies validate an HFD/AKR/J mouse model of PH‐HFpEF, which may offer a new avenue for testing potential mechanisms and treatments for this disease.
American Journal of Respiratory Cell and Molecular Biology | 2017
Neil J. Kelly; Josiah E. Radder; Jeffrey Baust; Christine L. Burton; Yen-Chun Lai; Karin Potoka; Brittani Agostini; John P. Wood; Timothy N. Bachman; Rebecca R. Vanderpool; Nadine Dandachi; Adriana S. Leme; Alyssa D. Gregory; Alison Morris; Ana L. Mora; Mark T. Gladwin; Steven D. Shapiro
&NA; Pulmonary hypertension (PH) is associated with features of obesity and metabolic syndrome that translate to the induction of PH by chronic high‐fat diet (HFD) in some inbred mouse strains. We conducted a genome‐wide association study (GWAS) to identify candidate genes associated with susceptibility to HFD‐induced PH. Mice from 36 inbred and wild‐derived strains were fed with regular diet or HFD for 20 weeks beginning at 6‐12 weeks of age, after which right ventricular (RV) and left ventricular (LV) end‐systolic pressure (ESP) and maximum pressure (MaxP) were measured by cardiac catheterization. We tested for association of RV MaxP and RV ESP and identified genomic regions enriched with nominal associations to both of these phenotypes. We excluded genomic regions if they were also associated with LV MaxP, LV ESP, or body weight. Genes within significant regions were scored based on the shortest‐path betweenness centrality, a measure of network connectivity, of their human orthologs in a gene interaction network of human PH‐related genes. WSB/EiJ, NON/ShiLtJ, and AKR/J mice had the largest increases in RV MaxP after high‐fat feeding. Network‐based scoring of GWAS candidates identified epidermal growth factor receptor (Egfr) as having the highest shortest‐path betweenness centrality of GWAS candidates. Expression studies of lung homogenate showed that EGFR expression is increased in the AKR/J strain, which developed a significant increase in RV MaxP after high‐fat feeding as compared with C57BL/6J, which did not. Our combined GWAS and network‐based approach adds evidence for a role for Egfr in murine PH.
American Journal of Respiratory Cell and Molecular Biology | 2017
Josiah E. Radder; Alyssa D. Gregory; Adriana S. Leme; Michael H. Cho; Yanxia Chu; Neil J. Kelly; Per Bakke; Amund Gulsvik; Augusto A. Litonjua; David Sparrow; Terri H. Beaty; James D. Crapo; Edwin K. Silverman; Yingze Zhang; Annerose Berndt; Steven D. Shapiro
&NA; Chronic obstructive pulmonary disease (COPD) is caused by a complex interaction of environmental exposures, most commonly cigarette smoke, and genetic factors. Chronic cigarette smoke exposure in the mouse is a commonly used animal model of COPD. We aimed to expand our knowledge about the variable susceptibility of inbred strains to this model and test for genetic variants associated with this trait. To that end, we sought to measure differential susceptibility to cigarette smoke‐induced emphysema in the mouse, identify genetic loci associated with this quantitative trait, and find homologous human genes associated with COPD. Alveolar chord length (CL) in 34 inbred strains of mice was measured after 6 months of exposure to cigarette smoke. After testing for association, we connected a murine candidate locus to a published meta‐analysis of moderate‐to‐severe COPD. We identified deleterious mutations in a candidate gene in silico and measured gene expression in extreme strains. A/J was the most susceptible strain in our survey (&Dgr; CL 7.0 ± 2.2 &mgr;m) and CBA/J was the least susceptible (&Dgr; CL −0.3 ± 1.2 &mgr;m). By integrating mouse and human genome‐wide scans, we identified the candidate gene Abi3bp. CBA/J mice harbor predicted deleterious variants in Abi3bp, and expression of the gene differs significantly between CBA/J and A/J mice. This is the first report of susceptibility to cigarette smoke‐induced emphysema in 34 inbred strains of mice, and Abi3bp is identified as a potential contributor to this phenotype.
Personalized Medicine | 2014
Josiah E. Radder; Steven D. Shapiro; Annerose Berndt
Chronic, complex diseases represent the majority of healthcare utilization and spending in the USA today. Despite this, therapeutics that account for the heterogeneity of these diseases are lacking, begging for more personalized approaches. Improving our understanding of disease phenotypes through retrospective trials of electronic health record data will enable us to better categorize patients. Increased usage of next-generation sequencing will further our understanding of the genetic variants involved in chronic disease. Utilization of data warehousing will be necessary in order to securely handle, integrate and analyze the large sets of data produced with these methods. Finally, increased use of clinical decision support will enable the return of clinically actionable results that physicians can use to apply these personalized approaches.
American Journal of Respiratory and Critical Care Medicine | 2017
Nadine Dandachi; Neil J. Kelly; John P. Wood; Christine L. Burton; Josiah E. Radder; Adriana S. Leme; Alyssa D. Gregory; Steven D. Shapiro
&NA; Rationale: Macrophage elastase (matrix metalloproteinase [MMP]‐12) is a potent protease that contributes to the lung destruction that accompanies cigarette smoking; it simultaneously inhibits lung tumor angiogenesis and metastasis by catalyzing the formation of antiangiogenic peptides. Recent studies have revealed novel nonproteolytic functions of MMP12, including antimicrobial activity through a peptide within its C‐terminal domain (CTD). Objectives: To determine whether the MMP12 CTD contributes to its antitumor activity in lung cancer. Methods: We used recombinant MMP12 peptide fragments, including its catalytic domain, CTD, and a 20 amino acid peptide within the CTD (SR20), in an in vitro system to delineate their effects on non‐small cell lung cancer cell proliferation and apoptosis. We translated our findings to two murine models of lung cancer, including orthotopic human xenograft and KrasLSL/G12D mouse models of lung cancer. Measurements and Main Results: We show that SR20 triggers tumor apoptosis by up‐regulation of gene expression of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and its receptor, death receptor 4, sensitizing cells to an autocrine loop of TRAIL‐mediated cell death. We then demonstrate the therapeutic efficacy of SR20 against two murine models of lung cancer. Conclusions: The MMP12 CTD initiates TRAIL‐mediated tumor cell death through its conserved SR20 peptide.
American Journal of Respiratory and Critical Care Medicine | 2017
Josiah E. Radder; Yingze Zhang; Alyssa D. Gregory; Shibing Yu; Neil J. Kelly; Joseph K. Leader; Naftali Kaminski; Frank C. Sciurba; Steven D. Shapiro
&NA; Rationale: Genetic association studies in chronic obstructive pulmonary disease have primarily tested for association with common variants, the results of which explain only a portion of disease heritability. Because rare variation is also likely to contribute to susceptibility, we used whole‐genome sequencing of subjects with clinically extreme phenotypes to identify genomic regions enriched for rare variation contributing to chronic obstructive pulmonary disease susceptibility. Objectives: To identify regions of rare genetic variation contributing to emphysema with severe airflow obstruction. Methods: We identified heavy smokers that were resistant (n = 65) or susceptible (n = 64) to emphysema with severe airflow obstruction in the Pittsburgh Specialized Center of Clinically Oriented Research cohort. We filtered whole‐genome sequencing results to include only rare variants and conducted single variant tests, region‐based tests across the genome, gene‐based tests, and exome‐wide tests. Measurements and Main Results: We identified several suggestive associations with emphysema with severe airflow obstruction, including a suggestive association of all rare variation in a region within the gene ZNF816 (19q13.41; P = 4.5 × 10−6), and a suggestive association of nonsynonymous coding rare variation in the gene PTPRO (P = 4.0 × 10−5). Association of rs61754411, a rare nonsynonymous variant in PTPRO, with emphysema and obstruction was demonstrated in all non‐Hispanic white individuals in the Pittsburgh Specialized Center of Clinically Oriented Research cohort. We found that cells containing this variant have decreased signaling in cellular pathways necessary for survival and proliferation. Conclusions: PTPRO is a novel candidate gene in emphysema with severe airflow obstruction, and rs61754411 is a previously unreported rare variant contributing to emphysema susceptibility. Other suggestive candidate genes, such as ZNF816, are of interest for future studies.
The Journal of Infectious Diseases | 2016
Yung Yi C. Mosley; Josiah E. Radder; Annerose Berndt; Harm HogenEsch
The objective of the current study was to investigate the genetics of antibody responses to an acellular pertussis vaccine by a genome-wide association study in mice. Female mice of 28 inbred strains received this vaccine at 6, 8, and 12 weeks of age. The antibody titer and avidity of immunoglobulin (Ig) G specific for diphtheria toxin, pertussis toxin, filamentous hemagglutinin and pertactin were measured at 14 and 24 weeks of age. The magnitude, longevity and avidity of IgG differed significantly among mouse strains. There was significant correlation between antigen-specific IgGs for longevity but not for magnitude and avidity. Association mapping and analysis with PolyPhen software identified 6 genetic markers associated with longevity for all 4 antigens, although the expression levels of these genes did not correlate with longevity phenotype. This study provides novel insights into the genetic basis and potential candidate genes for differences in the IgG responses to vaccination.
Current protocols in immunology | 2016
Neil J. Kelly; Nadine Dandachi; Dmitry A. Goncharov; Andressa Z. Pena; Josiah E. Radder; Alyssa D. Gregory; Yen-Chun Lai; Adriana S. Leme; Mark T. Gladwin; Elena A. Goncharova; Claudette M. St. Croix; Steven D. Shapiro
The quantification of tunica media thickness in histological cross sections is a ubiquitous exercise in cardiopulmonary research, yet the methods for quantifying medial wall thickness have never been rigorously examined with modern image analysis tools. As a result, inaccurate and cumbersome manual measurements of discrete wall regions along the vessel periphery have become common practice for wall thickness quantification. The aim of this study is to introduce, validate, and facilitate the use of an improved method for medial wall thickness quantification. We describe a novel method of wall thickness calculation based on image skeletonization and compare its results to those of common techniques. Using both theoretical and empirical approaches, we demonstrate the accuracy and superiority of the skeleton‐based method for measuring wall thickness while discussing its interpretation and limitations. Finally, we present a new freely available software tool, the VMI Calculator, to facilitate wall thickness measurements using our novel method.
Current protocols in immunology | 2016
Neil J. Kelly; Nadine Dandachi; Dmitry A. Goncharov; Andressa Z. Pena; Josiah E. Radder; Alyssa D. Gregory; Yen-Chun Lai; Adriana S. Leme; Mark T. Gladwin; Elena A. Goncharova; Claudette M. St. Croix; Steven D. Shapiro
The quantification of tunica media thickness in histological cross sections is a ubiquitous exercise in cardiopulmonary research, yet the methods for quantifying medial wall thickness have never been rigorously examined with modern image analysis tools. As a result, inaccurate and cumbersome manual measurements of discrete wall regions along the vessel periphery have become common practice for wall thickness quantification. The aim of this study is to introduce, validate, and facilitate the use of an improved method for medial wall thickness quantification. We describe a novel method of wall thickness calculation based on image skeletonization and compare its results to those of common techniques. Using both theoretical and empirical approaches, we demonstrate the accuracy and superiority of the skeleton‐based method for measuring wall thickness while discussing its interpretation and limitations. Finally, we present a new freely available software tool, the VMI Calculator, to facilitate wall thickness measurements using our novel method.